Quantcast
Last updated on April 17, 2014 at 11:05 EDT

Latest H5N1 clinical trials Stories

2012-04-30 02:26:20

MERIDEN, Conn., April 30, 2012 /PRNewswire/ -- Protein Sciences Corporation has expanded its senior management team by adding leaders in the areas of manufacturing and finance. The additions come at a time of great anticipation as the Company prepares for the launch of its first product, FluBlok®, a first-in-class recombinant vaccine for seasonal influenza. Mireli Fino joins us as VP, Manufacturing Operations. She comes from Wyeth (now Pfizer) where she spent the past 20 years in...

2012-04-25 02:31:31

PRINCETON, N.J., April 25, 2012 /PRNewswire/ -- Soligenix, Inc. (OTCBB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today further progress in the development of ThermoVax(TM), its proprietary vaccine thermostabilization technology. Progress has been based on additional characterization of the stability of prototype vaccines that have been kept at elevated temperatures in excess of three months. These studies are being conducted as part of a...

2012-04-05 09:46:20

Analysis by NIH-supported scientists may help identify requirements for HIV vaccine Insights into how the first vaccine ever reported to modestly prevent HIV infection in people might have worked were published online today in the New England Journal of Medicine. Scientists have found that among adults who received the experimental HIV vaccine during the landmark RV144 clinical trial (http://www.niaid.nih.gov/news/newsreleases/2009/pages/thaivaxstudy.aspx), those who produced relatively...

2012-03-21 02:24:23

NEWARK, Del., March 21, 2012 /PRNewswire/ -- iBio, Inc. (NYSE AMEX: IBIO) today announced completion of the first human trial of iBioLaunch-produced H1N1 influenza vaccine (HAC1) that began September 13, 2010. This Phase 1, single-blind, placebo-controlled, dose-escalation study was conducted to assess the safety and reactogenicity and immunogenicity of HAC1 produced by iBio's research collaborator, the Fraunhofer USA Center for Molecular Biotechnology. The trial was supported by funding from...

2012-03-07 03:00:00

BLUE BELL, Pa., March 7, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO) announced today that a global vaccine industry leader has joined the company's Scientific Advisory Board. Dr. Anthony Ford-Hutchinson, with over 30 years' experience in vaccine development and commercialization and formerly at Merck and Co., will contribute strategic business and scientific guidance as the company advances its preclinical and clinical-stage pipeline of synthetic vaccines for cancer,...

2012-02-29 00:35:15

Discovery provides new insights into inner workings of our immune system Scientists from Trinity College Dublin have discovered a new 'off switch' in our immune response which could be boosted in diseases caused by over-activation of our immune system, or blocked to improve vaccines. The findings are published this week in the journal Nature Communications. The research was funded by Health Research Board, Ireland and Science Foundation Ireland. The research team, led by Dr Anne...

2012-02-16 05:47:00

NES ZIONA, Israel, February 16, 2012 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. [http://www.biondvax.com ] (TASE: BNDX) today announced positive results from its second Phase II clinical trial (BVX-005) of the Universal Influenza Vaccine (Multimeric-001) developed by Biondvax for improving existing flu vaccines in elderly. The vaccine was found to be safe and well tolerated, and induced robust cellular and humoral immune responses in elderly patients (65+), successfully...

2012-02-16 03:30:00

ALBANY, New York, February 16, 2012 /PRNewswire/ -- New Report Added in ResearchMoz Reports DatabaseVaccine Production (Trends, Techniques, Key Players, Spending Estimates and Forecasts) [http://www.researchmoz.com/vaccine-production-trends-techniques-key-players-spending-estimates-and-forecasts-report.html ] The considerable revenue growth in the vaccine market over the past ten years suggests the amount of vaccine production and the techniques of vaccine production...

2012-02-06 06:00:00

PRINCETON, N.J., Feb. 6, 2012 /PRNewswire/ -- Soligenix, Inc. (OTCBB: SNGXD) (Soligenix or the Company), a development stage biopharmaceutical company, announced today results from preclinical studies of its proprietary vaccine thermostabilization technology indicating that Soligenix is able to produce stable vaccine formulations using adjuvants, protein immunogens, and other components that ordinarily would not withstand long temperature variations exceeding customary...

2012-01-09 07:00:00

ATLANTA, Jan. 9, 2012 /PRNewswire/ -- Robert McNally, Ph.D., President and CEO of GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), today issued the following letter to shareholders: Dear Fellow Shareholders, At the start of a new year, it is important to acknowledge all that we have accomplished over the past year, but it is even more crucial to focus our energies on the challenges and opportunities awaiting GeoVax in 2012 and beyond. Here is a recap of our recent achievements, which have put the...